NCT04620681View on ClinicalTrials.gov

CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

July 20, 2024

Study Completion Date

July 20, 2025

Conditions
Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia
Interventions
BIOLOGICAL

CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes

Infusion of mononuclear cells, apheresis products depleted of CD8+ T cells using the CliniMACS® system with CliniMACS® CD8 reagent

DRUG

Standard of Care Chemotherapy

Standard of care cytarabine-based chemotherapy

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT04620681 - CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML | Biotech Hunter | Biotech Hunter